Comparative Efficacy of Targeted Systemic Therapies for Mode…
Established
55
Citations43
Refs2022
Year
Search Works
Work Details
- DOI 10.1007/s13555-022-00721-1
- PMID https://pubmed.ncbi.nlm.nih.gov/35435637
- PMCID https://www.ncbi.nlm.nih.gov/pmc/articles/9110624
- OpenAlex ID W4223967404
- Type Review
- Language EN
- Published 18 Apr 2022
- Volume 12 (5)
- Pages 1181–1196
- Source Dermatology and Therapy
- Publisher Adis, Springer Healthcare
- FWCI 2.27
- Countries 3
- Institutions 7
- Added 19 Apr 2022
- Updated 28 Oct 2026
External Links
MENU
0
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
Review 2022 EN Gold
INTRODUCTION: The comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) has not been systematically assessed using recent phase 3 data. This network meta-analysis assesses the comparative efficacy of targeted systemic therapies without the addition of topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI) in adults with moderate to sev…
55
Citations
43
References
10
Authors
2.27
FWCI
Citations by Year
Last 5 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
10 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Jonathan I. Silverberg Corresponding | George Washington University (US) | |
| 2 | Hwanhee Hong | University of British Columbia (CA) Probity Medical Research (CA) | |
| 3 | Jacob Pontoppidan Thyssen | University of Copenhagen (DK) Bispebjerg Hospital (DK) | |
| 4 | Brian Calimlim | AbbVie (United States) (US) | |
| 5 | Avani D. Joshi | AbbVie (United States) (US) | — |
| 6 | Henrique D. Teixeira | AbbVie (United States) (US) | |
| 7 | Eric B. Collins | — | |
| 8 | Marjorie M. Crowell | — | — |
| 9 | Scott J. Johnson | — | |
| 10 | April Wang Armstrong | University of Southern Califor… (US) |
Related Works
10Data: OpenAlex